Health

Ozempic probed by EU drug regulator

Weight management medications under investigation after a small number of reports of suicidal risks were referred to the watchdog

Saxenda, which was only approved for reimbursement in Ireland in February of this year, is used to treat obesity, while Ozempic is used to treat diabetes. Picture: Getty

The European Union’s drug regulator has launched a probe into Novo Nordisk A/S’s weight-loss medications after a small number of reports of suicidal risks were referred to the watchdog.

The European Medicines Agency (EMA) is looking at adverse events noted by the Icelandic Medicines Agency. According to a statement from the EMA on Monday, these include two cases of suicidal thoughts linked to the drugs Saxenda and Ozempic.

Suicidal behaviour is not currently listed as ...